Table 3 Exploratory analysis of prognostic factors for OS
Covariates | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Number of prior therapies | ≥4 | 1.56 (0.81–2.99) | 0.176 |  |  |
Sex | Male | 0.66 (0.30–1.45) | 0.304 |  |  |
age | > 66 | 0.87 (0.46–1.64) | 0.671 |  |  |
ECOG PS | 2 | 1.61 (0.71–3.68) | 0.252 |  |  |
Location of primary tumor | Stomach | 1.12 (0.46–2.70) | 0.795 |  |  |
Histology | diffuse | 1.09 (0.55–2.16) | 0.801 |  |  |
HER2 overexpression | (+) | 1.59 (0.81–3.12) | 0.171 |  |  |
Concomitant use of NSAIDs/antiplatelets/anticoagulation therapy | (+) | 1.60 (0.80–3.18) | 0.18 |  |  |
History of hypertension | (+) | 0.71 (0.35–1.47) | 0.371 |  |  |
Number of metastatic sites | ≥2 | 1.86 (0.97–3.59) | 0.061 |  |  |
Ascites | (+) | 1.88 (0.99–3.56) | 0.05 |  |  |
Peritoneal metastasis | (+) | 0.79 (0.41–1.49) | 0.468 |  |  |
Previous gastrectomy | (+) | 0.71 (0.37–1.35) | 0.297 |  |  |
Time from initiation of 1st line therapy | ≥2 years | 0.67 (0.35–1.31) | 0.249 |  |  |
Prior history of ICI | (+) | 1.45 (0.68–3.10) | 0.329 |  |  |
ALP | ≥WNL | 1.28 (0.67–2.46) | 0.444 |  |  |
CRP | ≥WNL | 2.18 (1.02–4.61) | 0.041 | 1.72 (0.76–3.89) | 0.187 |
LDH | ≥WNL | 2.02 (1.04–3.91) | 0.037 | 1.66 (0.74–3.70) | 0.149 |
NLR | < 2.5 | 0.44 (0.20–0.93) | 0.033 | 0.56 (0.28–1.12) | 0.089 |
PLR | < 250 | 0.53 (0.28–1.01) | 0.052 |  |  |